|Bid||41.66 x 1100|
|Ask||45.77 x 800|
|Day's Range||43.73 - 45.64|
|52 Week Range||9.66 - 46.42|
|Beta (5Y Monthly)||3.06|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss just how good the biotech's latest clinical results were. Keith Speights: Let's talk about a small biotech that really hasn't been in the news much until just recently.
Every investor in Celldex Therapeutics, Inc. ( NASDAQ:CLDX ) should be aware of the most powerful shareholder groups...